Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework
Kamal S. Saini, Chris Twelves
British Journal of Cancer (2021) Vol. 125, Iss. 2, pp. 155-163
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Molecular targeted therapy for anticancer treatment
Hye‐Young Min, Ho‐Young Lee
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1670-1694
Open Access | Times Cited: 240
Drug-tolerant persister cells in cancer: the cutting edges and future directions
Yi Pu, Lu Li, Haoning Peng, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 799-813
Closed Access | Times Cited: 59
Locoregional drug delivery for cancer therapy: Preclinical progress and clinical translation
Suyog Shaha, Danika Rodrigues, Samir Mitragotri
Journal of Controlled Release (2024) Vol. 367, pp. 737-767
Closed Access | Times Cited: 19
Illness trajectories of incurable solid cancers
Eric C.T. Geijteman, Evelien Kuip, Jannie Oskam, et al.
BMJ (2024), pp. e076625-e076625
Open Access | Times Cited: 11
Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy
Yu Lu, Di Zhu, Quynh Chi Le, et al.
Nanoscale (2022) Vol. 14, Iss. 44, pp. 16339-16375
Open Access | Times Cited: 32
A comprehensive review of the anticancer effects of decursin
Yueming Chu, Qiang Yuan, Hangyu Jiang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study
C. Gallois, Elisabeth Bergen, Édouard Auclin, et al.
ESMO Open (2024) Vol. 9, Iss. 9, pp. 103696-103696
Open Access | Times Cited: 5
Advancing real-world research in thoracic malignancies: learnings from the international I-O Optimise initiative
Søren Paaske Johnsen, Paul Baas, Jens Benn Sørensen, et al.
Future Oncology (2025), pp. 1-12
Open Access
Real‐world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer—Analysis of the Prospective Dutch Colorectal Cancer cohort
Sietske C. van Nassau, Koen Zwart, Frederieke H. van der Baan, et al.
International Journal of Cancer (2025)
Open Access
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
Kamal S. Saini, Kevin Punie, Chris Twelves, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 7, pp. 945-962
Open Access | Times Cited: 32
Efficacy and safety of first‐line treatments for patients with advanced anaplastic lymphoma kinase mutated, non–small cell cancer: A systematic review and network meta‐analysis
Peng Yang, Qiang Zhao, Ziyi Liao, et al.
Cancer (2023) Vol. 129, Iss. 8, pp. 1261-1275
Open Access | Times Cited: 11
Role of Folate Receptor and CD44 in Targeting of Docetaxel and Paclitaxel Fabricated Conjugates for Efficient Cancer Therapy
Amol Tatode, Pranav Agrawal, Jayshree Taksande, et al.
Journal of Medicine Surgery and Public Health (2024), pp. 100163-100163
Open Access | Times Cited: 4
Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue
Rossella Loria, Patrizia Vici, Francesca Sofia Di Lisa, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 18
The role of mesenchymal stem cells derived exosomes as a novel nanobiotechnology target in the diagnosis and treatment of cancer
You Zhou, Yuqing Dong, Aixue Zhang, et al.
Frontiers in Bioengineering and Biotechnology (2023) Vol. 11
Open Access | Times Cited: 10
Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma
Luciano J. Costa, Smith Giri, Susan Bal, et al.
British Journal of Haematology (2023) Vol. 200, Iss. 6, pp. 824-827
Open Access | Times Cited: 7
Comprehensive characterization and development of multi-core shell superparamagnetic nanoparticles for controlled delivery of drugs and their kinetic release modelling
Simone Gonçalves Moretto, Adriano S. Silva, Jose L. Díaz de Tuesta, et al.
Materials Today Chemistry (2023) Vol. 33, pp. 101748-101748
Open Access | Times Cited: 7
Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials
Ho Wai Derrick Siu, Frank Lin, Doah Cho, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 2
Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer
Ryunosuke Hoshi, Kristyna A. Gorospe, Hagar I. Labouta, et al.
Pharmaceutics (2024) Vol. 16, Iss. 9, pp. 1181-1181
Open Access | Times Cited: 2
Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence
Yongmei Wang, Fanbo Jing, Haibo Wang
Advances in Therapy (2022) Vol. 39, Iss. 2, pp. 862-891
Closed Access | Times Cited: 11
Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
Véronique Roche, Víctor Sandoval, Claire Wolford, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e006205-e006205
Open Access | Times Cited: 5
Citation: Trybus, E.; Trybus, W. H1 Antihistamines—Promising Candidates for Repurposing in the Context of the Development of New Therapeutic Approaches to Cancer Treatment. Cancers 2024, 16, 4253. https://doi.org/10.3390/cancers16244253
Ewa Trybus, Wojciech Trybus
Cancers (2024) Vol. 16, Iss. 24, pp. 4253-4253
Open Access | Times Cited: 1
Editorial: Recent advances in discovering molecular targets for cancer therapy
Zhaoqi Yang, Teng Wang
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 1
The role of stereotactic body radiotherapy in oligoprogressive malignant disease (RADIANT): oncologic outcomes from a phase 2 non-randomized controlled trial
Rachel Glicksman, Srinivas Raman, Xiang Y. Ye, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 121, Iss. 2, pp. 292-306
Open Access | Times Cited: 1
Determining Line of Therapy from Real‐World Data in Non‐Small Cell Lung Cancer
Connor B. Grady, Wei‐Ting Hwang, Joshua E. Reuss, et al.
Pharmacoepidemiology and Drug Safety (2024) Vol. 33, Iss. 12
Closed Access | Times Cited: 1
Development of a Machine Learning Model Using Limited Features to Predict 6-Month Mortality at Treatment Decision Points for Patients With Advanced Solid Tumors
George Chalkidis, Jordan P. McPherson, Anna C. Beck, et al.
JCO Clinical Cancer Informatics (2022), Iss. 6
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top